Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Jena – page 2

349 clinical trials in Jena, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Jena at a glance
349
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

349 trials in Jena

Open in trial search

Coeliac disease

Recruiting

Study on ZED1227 for Improving Symptoms in Celiac Disease Patients on a Gluten-Free Diet

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Methyl (E,6S)-7-[[1-[2-(2-Ethylbutylamino)-2-Oxoethyl]-2-Oxopyridin-3-Yl]Amino]-6-[(3-Methylimidazole-4-Carbonyl)Amino]-7-Oxohept-2-Enoate
  • Sponsor:Dr. Falk Pharma GmbH

Neoplasm malignant

Recruiting

Study on Long-term Safety of Nivolumab and Drug Combination for Cancer Patients from Previous BMS Trials

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Conjunctivitis allergic

Recruiting

Study on the Effectiveness of PQ Grass for Children and Teens with Seasonal Allergies from Grass Pollen

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Desloratadine
  • Sponsor:Allergy Therapeutics (UK) Limited

Amyotrophic lateral sclerosis

Recruiting

Study on the Safety and Effectiveness of Dazucorilant for Patients with Amyotrophic Lateral Sclerosis (ALS)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dazucorilant
  • Sponsor:Corcept Therapeutics Inc.

Heart failure with reduced ejection fraction

Recruiting

A study of the safety and efficacy of AC01 in patients with heart failure with reduced ejection fraction

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:AnaCardio AB

Autoimmune hepatitis

Recruiting

A Phase 2/3 Randomized Double‑Blind Study of Inebilizumab for Safety and Tolerability in Patients with Autoimmune Hepatitis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Inebilizumab
  • Sponsor:Amgen Inc.

Staphylococcal bacteraemia

Recruiting

Safety and Pharmacokinetics of MIB2 (StaphAcute) in Healthy Volunteers and Patients with Staphylococcus aureus Bacteremia

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Sodium Chloride
  • Sponsor:University Of Cologne

Gastrointestinal stromal tumour

Recruiting

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib Mesilate
  • Sponsor:Glaxosmithkline Research & Development Limited

Polycythaemia vera

Recruiting

A Phase 3 Study of Sapablursen Compared with Placebo in Adults with Polycythemia Vera

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sapablursen
  • Sponsor:Deciphera Pharmaceuticals Inc.

Immune thrombocytopenia

Recruiting

Phase 3 Study of Romiplostim Combined with Prednisolone versus Prednisolone Alone in Adults with Previously Untreated Primary Immune Thrombocytopenia (ITP)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:Amgen Inc.

Colitis ulcerative

Recruiting

Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Heart failure with preserved ejection fraction

Recruiting

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Jena

What the registry says about research in the country

01 Oncology Research

Advanced clinical trials focusing on multiple myeloma, prostate cancer, and gastric cancer treatments. Studies evaluating novel therapeutic combinations and targeted approaches for various cancer types.

  • Hematologic Malignancies
  • Solid Tumors
  • Targeted Therapies

Innovative treatments including antibody-drug conjugates and immunotherapy combinations for improved patient outcomes.

02 Cardiovascular Studies

Research investigating treatments for hypertrophic cardiomyopathy and advanced cardiovascular disease. Trials exploring new approaches to reduce major cardiovascular events and improve patient quality of life.

  • Heart Disease Management
  • Cardiovascular Risk Reduction
  • Novel Therapeutic Approaches

Focus on both preventive measures and treatment of established cardiovascular conditions.

03 Autoimmune Disorders

Clinical investigations of treatments for systemic lupus erythematosus, Sjögren's Disease, and other autoimmune conditions. Studies evaluating new biological therapies and targeted treatments.

  • Inflammatory Diseases
  • Immunotherapy
  • Disease-Modifying Treatments

Comprehensive research into improving treatment outcomes for patients with chronic autoimmune conditions.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.